Passive Biotech Equities

First Trust NYSE Arca Biotechnology Index Fund

The First Trust NYSE® Arca® Biotechnology Index Fund (the “Fund”) seeks investment results that correspond generally to the price and yield (before the Fund’s fees and expenses) of an equity index called the NYSE® Arca® Biotechnology Index (the “Index”).

$142.59

-10.2% last 12 months

Compare similar ETFs

Fund Size
Dividend
Fees
Current
NYSE Arca Biotechnology Index Fund FBT
Fund Size
$1.29 Billion
Dividend
0.0%
Fees
-
Total Stock Market Index Fund VTI
Fund Size
$1.46 Trillion
Dividend
1.4%
Fees
0.03%
500 Index Fund VOO
Fund Size
$982 Billion
Dividend
1.4%
Fees
0.03%
Total International Stock Index Fund VXUS
Fund Size
$404 Billion
Dividend
3.4%
Fees
0.07%
Core S&P 500 ETF IVV
Fund Size
$402 Billion
Dividend
1.4%
Fees
0.03%
View 1287 similar ETFs →

Average metrics of all companies in portfolio

Compare to
Market
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $26.8 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 0.24 %
Beta Indicates the relationship between the price performance of a share and the market. 0.7509
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 29.31
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -23.09
Profitable Companies 63
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 65.75
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 5.54
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company -2.87
Compare to
Market
Enterprise Value to EBIT Enterprise Value divided by EBIT 5.08
Enterprise Value to Revenue Enterprise value divided by revenue 5.57
Total Debt to Enterprise Value Total debt divided by enterprise value 0.12
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.1289
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 114.28%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
Return on Equity Equity divided by market cap. -15.46%
Return on Assets Indicates a company's profitability in relation to its total assets. 3.53%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 1.92%

Industries

Healthcare 96.8%
N/A 3.2%

Market cap

Micro Cap 0%
Small Cap 7%
Mid Cap 21%
Large Cap 71%
Mega Cap 0%

31 Investments

P/E-Ratio
Total Investment
Weight
Ultragenyx Pharmaceutical Inc logo

RARE - Manufacturing

Ultragenyx Pharmaceutical Inc

P/E-Ratio
-5.9
Total Investment
$54.5 Million
Weight
4.2%
Grifols SA logo

GRFS - Manufacturing

Grifols SA

P/E-Ratio
7.7
Total Investment
$53.9 Million
Weight
4.2%
ACADIA Pharmaceuticals Inc logo

ACAD - Manufacturing

ACADIA Pharmaceuticals Inc

P/E-Ratio
-45.9
Total Investment
$53.3 Million
Weight
4.1%
Charles River Laboratories Int logo

CRL - Professional, Scientific, and Technical Services

Charles River Laboratories Int

P/E-Ratio
24.7
Total Investment
$48.1 Million
Weight
3.7%
IQVIA Holdings Inc logo

IQV - Health Care and Social Assistance

IQVIA Holdings Inc

P/E-Ratio
30.4
Total Investment
$47.4 Million
Weight
3.7%
Moderna Inc logo

MRNA - Manufacturing

Moderna Inc

P/E-Ratio
-8.3
Total Investment
$46.7 Million
Weight
3.6%
Bio-Techne Corp logo

TECH - Manufacturing

Bio-Techne Corp

P/E-Ratio
43.6
Total Investment
$45.4 Million
Weight
3.5%
Neurocrine Biosciences Inc logo

NBIX - Manufacturing

Neurocrine Biosciences Inc

P/E-Ratio
52.8
Total Investment
$45 Million
Weight
3.5%
Mettler-Toledo International I logo

MTD - Manufacturing

Mettler-Toledo International I

P/E-Ratio
32.3
Total Investment
$44.9 Million
Weight
3.5%
Alnylam Pharmaceuticals Inc logo

ALNY - Manufacturing

Alnylam Pharmaceuticals Inc

P/E-Ratio
-41.5
Total Investment
$44.6 Million
Weight
3.5%
BioMarin Pharmaceutical Inc logo

BMRN - Manufacturing

BioMarin Pharmaceutical Inc

P/E-Ratio
101.4
Total Investment
$44.3 Million
Weight
3.4%
Illumina Inc logo

ILMN - Manufacturing

Illumina Inc

P/E-Ratio
-16.0
Total Investment
$43.9 Million
Weight
3.4%
BioNTech SE logo

BNTX - Manufacturing

BioNTech SE

P/E-Ratio
19.9
Total Investment
$43.8 Million
Weight
3.4%
QIAGEN NV logo

QGEN - Manufacturing

QIAGEN NV

P/E-Ratio
26.4
Total Investment
$43.7 Million
Weight
3.4%
Exact Sciences Corp logo

EXAS - Professional, Scientific, and Technical Services

Exact Sciences Corp

P/E-Ratio
-56.4
Total Investment
$43.4 Million
Weight
3.4%
Incyte Corp logo

INCY - Professional, Scientific, and Technical Services

Incyte Corp

P/E-Ratio
19.8
Total Investment
$43 Million
Weight
3.3%
Exelixis Inc logo

EXEL - Professional, Scientific, and Technical Services

Exelixis Inc

P/E-Ratio
32.8
Total Investment
$42.9 Million
Weight
3.3%
Vertex Pharmaceuticals Inc logo

VRTX - Manufacturing

Vertex Pharmaceuticals Inc

P/E-Ratio
28.1
Total Investment
$42.4 Million
Weight
3.3%
Ionis Pharmaceuticals Inc logo

IONS - Manufacturing

Ionis Pharmaceuticals Inc

P/E-Ratio
-16.2
Total Investment
$41.4 Million
Weight
3.2%
Regeneron Pharmaceuticals Inc logo

REGN - Manufacturing

Regeneron Pharmaceuticals Inc

P/E-Ratio
24.4
Total Investment
$41 Million
Weight
3.2%
Genmab A/S logo

GMAB - Professional, Scientific, and Technical Services

Genmab A/S

P/E-Ratio
0.0
Total Investment
$40.3 Million
Weight
3.1%
BEIGENE LTD logo

BGNE - Manufacturing

BEIGENE LTD

P/E-Ratio
-14.3
Total Investment
$39.5 Million
Weight
3.1%
Alkermes PLC logo

ALKS - Manufacturing

Alkermes PLC

P/E-Ratio
11.3
Total Investment
$39.4 Million
Weight
3.1%
Agios Pharmaceuticals Inc logo

AGIO - Manufacturing

Agios Pharmaceuticals Inc

P/E-Ratio
1.0
Total Investment
$39.3 Million
Weight
3.1%
Gilead Sciences Inc logo

GILD - Manufacturing

Gilead Sciences Inc

P/E-Ratio
14.5
Total Investment
$39.3 Million
Weight
3.1%
To improve your user experience we use cookies.